Imunon, Inc. (IMNN) Earnings

Management highlights

- Clinical Data Validation and Platform Progress * Final Phase 2 Ovation 2 data for Immunon001 shows a consistent, clinically meaningful 14.7-month improvement in median overall survival in newly diagnosed ovarian cancer patients, alongside a favorable safety profile that addresses historic systemic IL-12 barriers. Translational findings show lower rates of minimal residual disease (MRD), higher circulating tumor DNA (ctDNA) clearance, and higher rates of no evidence of disease (NED) after frontline therapy. * Preliminary data from the investigator-led Phase 2 MRD trial (in collaboration with Breakthrough Cancer, led by MD Anderson) in patients post-frontline treatment shows: 44% MRD positivity in the Immunon001 arm vs 67% in control; 87.5% ctDNA clearance vs 62% in control; 100% NED achievement vs 56% in control. No cytokine release syndrome, systemic toxicities, or serious immune-related adverse events have been observed, confirming the favorable safety profile. Translational analyses confirm the proposed mechanism of action: local IL-12 expression remodels immunologically cold ovarian tumors to an active, hot immune state. * New data from Immunon001 has been accepted for presentation at the November 2026 SITC (CITSE) conference, and the company presented platform technology at the July 2026 AACR D3 Congress. - Phase 3 Ovation 3 Enrollment and Execution * Ovation 3 is a pivotal Phase 3 trial evaluating Immunon001 plus standard of care chemotherapy in newly diagnosed advanced epithelial ovarian cancer. The trial is executing well ahead of internal plans, with current enrollment of 0.5 patients per site per month, exceeding the 0.3 patients per site per month plan and the historical average of 0.2 patients per site per month for ovarian cancer trials. * Site activation has proceeded faster than industry benchmarks, with 35% of planned sites already active or in activation, and double the required number of additional sites identified to complete enrollment. Enrollment momentum reflects strong investigator enthusiasm, high prescreening-to-randomization conversion, and operational efficiencies that do not delay standard care. Patient compliance and data quality are excellent, and the independent Data Monitoring Committee identified no new safety concerns. - Business and Capital Management * The company completed an up-to-$10 million non-dilutive financing in June 2026 structured as non-redeemable, non-convertible preferred stock and secured promissory notes with no warrants, to support the Ovation 3 program. Management and employees have voluntarily opted to take a meaningful portion of their compensation in equity to align with shareholders and preserve cash. Additional capital will be required to complete the Phase 3 trial, and the company is actively exploring disciplined financing options. * The company will host an R&D Day in New York City on September 23, 2026 to provide deeper insight into Immunon001 and platform technology.

Guidance

- The company confirms it maintains its original Ovation 3 enrollment target completion timeline of first half 2029; enrollment is currently tracking ahead of internal expectations, and management confirms confidence in meeting or potentially accelerating this timeline, though no formal revision to the timeline has been announced. - Cash and cash equivalents of $6.9 million, combined with the June 2026 financing and ongoing cost discipline, are projected to provide operating runway through the end of 2026. Additional capital will be required to fully execute the Phase 3 trial and cover general and administrative needs going forward. - Final overall survival data from the Phase 2 Ovation 2 study is planned for submission to a major medical conference and presentation in early 2027.

Segment performance

Immunon is a clinical-stage biotechnology company with no commercial product segments currently generating revenue. All operating activity is focused on clinical development of lead candidate Immunon001. For Q2 2026: Research and development expenses were $1.5 million (up from $1.2 million in Q2 2025, driven by higher clinical and manufacturing costs for the Ovation 3 Phase 3 trial). General and administrative expenses were $1.3 million (down 20% from $1.6 million in Q2 2025, reflecting ongoing cost containment initiatives). Net cash used in operating activities was $3.0 million, down from $4.0 million in Q1 2026. As of June 30, 2026, cash and cash equivalents totaled $6.9 million.

Risks & headwinds

- The Phase 2 MRD trial is small and was not powered for statistical significance, so there is uncertainty whether it will achieve a statistically significant improvement in MRD endpoints, even with the large observed treatment effect to date. - Clinical trial enrollment is subject to seasonal variability: historically, ovarian cancer diagnoses and clinical trial enrollment are lower in summer months, which could create near-term enrollment fluctuations. While the company has maintained strong enrollment through the current summer season, this seasonal effect could still impact future enrollment rates. - There is no established standard for MRD assessment in ovarian cancer, and the field is still emerging, so the regulatory and clinical acceptance of MRD as a prognostic and efficacy endpoint is uncertain. - Additional capital raising will be required to advance the Phase 3 trial, and there is no guarantee that financing will be available on acceptable terms, or at all, which could impact the company's ability to complete trial execution.

Analyst Q&A

• Q: Will the Phase 2 MRD trial achieve statistically significant MRD improvement, will new data be presented at the September R&D Day, and is current strong enrollment sustainable, potentially accelerating the H1 2029 enrollment timeline?

  A: The MRD trial is small and was not powered for statistical significance, but the large observed effect may still yield a significant result as enrollment completes. The trial's lead principal investigator will present trial learnings at R&D Day, but no mature ctDNA data from Ovation 3 will be available. Strong enrollment is sustainable: careful site planning, prior Ovation 2 investigator experience, and a pipeline of new activated sites keep the trial on track to its current timeline, with performance exceeding expectations even accounting for expected summer seasonality.

• Q: When will the MRD trial complete enrollment, will results be published, is GOG involved, and is patient commitment to required second-look laparoscopy challenging?

  A: The MRD trial is expected to reach full enrollment by the end of 2026, after which patients will complete observation and assessment per protocol. All results will be published and presented at scientific forums. GOG is not formally involved in the MRD trial, though GOG sites are participating in Ovation 3, and the company has received strategic input from GOG for the Phase 3 program. All patients consent to the second-look laparoscopy as a requirement for enrollment, and the trial's data will generate critical insights linking surgical MRD findings to non-invasive blood-based assays to advance the field. To date, the trial has already confirmed that Immunon001 can be safely administered with Bevacizumab, a key early milestone.

• Q: Does site enrollment productivity increase over time, is there a difference in screening/enrollment rates between HRD-positive and HRD-negative patients, and when are the Ovation 3 interim analyses expected?

  A: Enrollment productivity does generally increase as site staff gain experience with the protocol and product, with a very fast learning curve for new sites. No meaningful difference in screening or enrollment rates has been observed between HRD-positive and HRD-negative patient groups, with patients enrolling equally across subgroups. Ovation 3 interim analyses are event-driven (tied to death events in the control arm) per the FDA-agreed trial design, and will not begin until after full trial enrollment. Further details on interim analysis timing will be shared once the trial matures.

• Q: What is the plan for site activations over the coming months?

  A: 35% of planned sites are already active or in active activation, and the company has identified twice the number of additional sites needed to hit the enrollment target. The company is tracking well against its activation plan, with strong inbound investigator interest, and expects to stay aligned with the current enrollment timeline.